The purpose of the study is to assess the safety profile of Depakote Sprinkle Capsules in the treatment of partial seizures in children ages 3-10.

Ages Eligible for Study:  3 Years   -   10 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

Subject has diagnosis of partial seizures with/without secondary generalization, supported by:

• Observed ictal events consistent with partial seizures: With/without secondary generalization; Documented by reliable observers
• 1 of following 2: EEG at some time in past demonstrating focal abnormalities consistent with partial seizures; OR, in absence of demonstrable EEG abnormality: MRI/CT scan evidence of a focal CNS lesion consistent with partial seizures
• On stable dose of 1 or 2 antiepileptic drug(s) other than valproate, for at least 1 month
• Not taking valproate or is currently receiving valproate resulting in a trough concentration of less than 40 mcg/mL
• History of at least 4 partial seizures/month in 2 months prior to screening
• Parent/caregiver is able to keep an accurate seizure diary

Exclusion Criteria:

• History of any of following: *Lennox-Gastaut syndrome; *Primary generalized seizures; *Infantile spasms; *Mixed seizure disorders including atypical absence; *Myoclonic or atonic seizures; *Pseudoseizures or Epilepsia Partialis Continuans (EPC)
• Has had status epilepticus in the past 6 months
• Has significant history of any of the following that would confound study results: *Cardiac (including clinically important abnormality on ECG); *Renal; *Psychiatric (including psychosurgery); *Oncologic; *Endocrine; *Metabolic; *Pancreatic; *Hepatic disease (including clinical/serological history of hepatitis); *Urea cycle disorder
• Has: *Expanding CNS neoplasm; *Active CNS infection; *Demyelinating disease; *Degenerative neurological disease; *progressive Encephalopathy; Or *any progressive CNS disease
• Has platelet count less than or equal to 100,000/mcL
• Has blood chemistry ALT/AST value(s) greater than or equal to 2 times upper limit of normal at screening
• Requires anticoagulant drug therapy
• Not expected to be able to maintain same dose of all pre-study anti-epileptic drugs (AEDs), excluding valproate, throughout study
• Receiving systemic chemotherapy
• Has taken lamotrigine, felbamate, or pemoline, within past 3 months prior to screening
• Has been on ketogenic diet within 30 days prior to screening
• Considered by investigator to be non-responder to valproate for treatment of epilepsy (e.g., Despite adequate trial with serum concentrations of 60 mcg/mL or greater, subject continues to have inadequate seizure control)